Phase 0 studies are microdose studies in humans conducted under an exploratory IND or clinical trial application

*RDEA119 and our other MEK inhibitors are being developed under a global license agreement with Bayer HealthCare.

For more information regarding these programs please click here to view our most recent company presentation.